# MONOCLONAL ANTIBODIES TO HUMAN SARCOMA MEMBRANE ANTIGENS

> **NIH NIH R01** · UNIVERSITY OF ILLINOIS AT CHICAGO · 1989 · $123,761

## Abstract

Human soft tissue sarcomas are malignant tumors arising in the
extraskeletal connective tissues of the body.  For the past several
years we have been involved in producing murine monoclonal
antibodies (MAbs) to cell surface sarcoma-associated antigens and
have generated 16 MAbs defining 9 antigenic systems.  In this
proposed continuation project we intend to identify those MAbs
which have potential clinical usefulness in the diagnosis of this
diverse group of tumors and in improving therapy.  The specific
aims of this research proposal are:  1) To perform a complete
binding specificity analysis on all MAbs produced.  Specificity
testing will be done on membrane preparations of fresh surgical
tissues, cultured and fresh cells, tissue sections, and
biochemically-characterized antigens.  2) To continue to produce
MAbs to sarcoma-associated antigens.  We will use protocols
optimized during our present study as well as new approaches
designed to generate MAbs with broad sarcoma specificity,
sarcoma subtype specificity, and specificity for shed antigens.  3)
Analysis of MAb immunohistochemically results with tissue
sections for utility in aiding pathologic diagnosis.  The MAbs will
be assessed for ability to discriminate tumor from normal,
sarcoma from nonsarcoma, different sarcoma subtypes, and
degree of differentiation (grade).  4) Use of MAbs against shed
antigens for the detection and quantitation of tumor markers in
sera of sarcoma patients.  Marker levels will be correlated with
tumor burden, surgery, response to therapy, and clinical course.
5) Analysis of radiolabeled MAbs in a human sarcoma xenograft-
athymic mouse model for ability to localize to tumor after in vivo
administration.  These studies will focus on MAbs with high
binding constants for cell surface sarcoma-associated antigens.  6)
Analysis of the therapeutic activity of MAbs and MAbs conjugated
with chemotherapy drugs when tested in vitro and in the athymic
mouse model.  These studies will focus on MAbs identified in
Specific Aim 5 as showing significant in vivo tumor localization.

Our long-term goals involve the clinical application of the MAbs
in pathologic diagnosis, prognosis, monitoring clinical course, and
therapy.  MAbs identified in this project may be entered into our
on-going clinical tumor imaging studies.

## Key facts

- **NIH application ID:** 3172930
- **Project number:** 5R01CA035354-06
- **Recipient organization:** UNIVERSITY OF ILLINOIS AT CHICAGO
- **SAM.gov UEI:** W8XEAJDKMXH3
- **Principal Investigator:** TAPAS K. DAS GUPTA
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $123,761
- **Award type:** 5
- **Project period:** 1984-04-01 → 1991-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3172930

## Citation

> US National Institutes of Health, RePORTER application 3172930, MONOCLONAL ANTIBODIES TO HUMAN SARCOMA MEMBRANE ANTIGENS (5R01CA035354-06). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3172930. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*